Elevated Serum Concentration of Adipocyte Fatty Acid-Binding Protein Correlates with the Markers of Abdominal Obesity Independently of Thyroid Hormones in Non-Obese Women with Polycystic Ovary Syndrome

Polak, Aleksandra; Łebkowska, Agnieszka; Krentowska, Anna; Buczyńska, Angelika; Adamski, Marcin; Krętowski, Adam; Kowalska, Irina; Adamska, Agnieszka

doi:10.3390/jcm12144610

Cited by 1 publication

(1 citation statement)

References 44 publications

(64 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study, we observed a slight increase in TSH and T4, which is positively correlated with the high FABP4 levels [26]. Polak et al recently reported, in a study of 66 females with polycystic ovary syndrome (PCOS) and 67 healthy controls, that serum concentrations of FABP4 were significantly higher in the PCOS group compared to the control group [27]. Another study, including an equal number of subclinical hypothyroid, overt hypothyroid, and healthy patients (n = 40 in each group), found that in patients with subclinical and overt hypothyroidism, the level of FABP4 was high, and the elevation closely correlated with high TSH [28].…”

Section: Discussionsupporting

confidence: 69%

Investigating the Role of FABP4 in Diabetes and Obesity and the Influence of Age and Ethnicity: A Comprehensive Analysis of a Cohort from the KEDP-Study

Abdalla,

Abubaker,

Abu-Farha

et al. 2024

IJMS

View full text Add to dashboard Cite

Adipocyte P2 (aP2), also known as FABP4, is an adipokine that adipose tissue produces and expresses in macrophages. Its primary role is to facilitate the transportation of fatty acids across cell membranes. Numerous studies have reported associations between FABP4 and the development of metabolic disorders. However, there is limited knowledge regarding FABP4 expression in diabetes and obesity, especially about different age groups, genders, and ethnicities. This study aims to investigate the association between FABP4 levels, diabetes mellitus, and obesity within various ethnic groups. We measured plasma FABP4 concentrations in a cohort of 2083 patients from the KDEP study and gathered anthropometric data. Additionally, we collected and analyzed clinical, biochemical, and glycemic markers using multivariate regression analysis. The average FABP4 concentration was significantly higher in female participants than in males (18.8 ng/mL vs. 14.4 ng/mL, p < 0.001, respectively), and in those over 50 years old compared to those under 50 years of age (19.3 ng/mL vs. 16.2 ng/mL, p < 0.001, respectively). In this study, significant positive associations were found between the plasma level of FABP4 and obesity markers: BMI (r = 0.496, p < 0.001), hip circumference (r = 0.463, p < 0.001), and waist circumference (WC) (r = 0.436, p < 0.001). Similar observations were also seen with glycemic markers, which included HbA1c (r = 0.126, p < 0.001), fasting blood glucose (FBG) (r = 0.184, p < 0.001), fasting insulin (r = 0.326, p < 0.001), and HOMA-IR (r = 0.333, p < 0.001). Importantly, these associations remained significant even after adjusting for age, gender, and ethnicity. Furthermore, FABP4 levels were negatively associated with male gender (β: −3.85, 95% CI: −4.92, −2.77, p < 0.001), and positively associated with age (β: 0.14, 95% CI: 0.096, 0.183, p < 0.001), BMI (β: 0.74, 95% CI: 0.644, 0.836, p < 0.001), and fasting insulin (β: 0.115, 95% CI: 0.091, 0.138, p < 0.001). In this study, plasma FABP4 levels were significantly higher in diabetic and obese participants, and they were strongly influenced by age, gender, and ethnicity. These findings suggest that FABP4 may serve as a valuable prognostic and diagnostic marker for obesity and diabetes, particularly among female patients, individuals over 50 years old, and specific ethnic groups.

show abstract

Section: Discussionsupporting

confidence: 69%